scholarly journals Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice

2001 ◽  
Vol 124 (3) ◽  
pp. 486-491 ◽  
Author(s):  
C. A. Jonsson ◽  
H. Carlsten
Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2468-2468
Author(s):  
Kenji Ishitsuka ◽  
Teru Hideshima ◽  
Makoto Hamasaki ◽  
Raje Noopur ◽  
Kumar Shaji ◽  
...  

Abstract Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme required for the de novo synthesis of guanine nucleotides from IMP. VX-944 (Vertex Pharmaceuticals, Cambridge, MA) is a small molecule, selective, uncompetitive novel inhibitor directed against human IMPDH enzyme. IMPDH inhibitors have been demonstrated to induce growth arrest, and extensively investigated as immunosuppressants. Here we show that VX-944 inhibits growth of human multiple myeloma (MM) cell lines, including those resistant to conventional agents, via induction of apoptosis and S phase arrest in vitro. Interleukin-6, insulin-like growth factor-1, or co-culture with bone marrow stromal cells (BMSCs), do not protect against VX-944-induced MM cell growth inhibition. We next delineated the molecular mechanism of VX-944-induced MM cell death in the MM.1S human MM cell line. VX-944 induced apoptosis in MM.1S cells, confirmed by PARP cleavage as well as flow cytometric detection of the mitochondrial membrane protein 7A6 and TdT-mediated dUTP nick-end labelling (TUNEL) positive cells, without significant cleavage of caspases 3, 8 and 9. While the pan-caspase inhibitor z-VAD-fmk did not inhibit the VX-944-induced apoptosis and cell death suggesting that VX-944 triggers apoptosis in MM1.S cells primarily via caspase-independent pathway. Importantly, VX-944 augments the cytotoxicity of doxorubicin, melphalan and bortezomib, all of which activate caspases in MM cells and induce apoptosis, even in the presence of BMSCs. Taken together, our data demonstrate non-caspase-dependent apoptotic pathway triggered by VX-944 thereby providing a rationale to enhance MM cell cytotoxicity by combining this agent with conventional and/or novel agents which trigger caspase activation. Our ongoing studies are delineating the mechanisms whereby VX-944 induces MM cell apoptosis.


1994 ◽  
Vol 5 (5) ◽  
pp. 340-343 ◽  
Author(s):  
J. M. Woods ◽  
C. L. P. Marr ◽  
C. R. Penn

1-β-D-Ribofuranosylpyrazole-3,4-dicarboxamide (GR-92938X) was found to be an inhibitor of respiratory syncytial virus in vitro, with a potency equivalent to that of ribavirin. The compound was more specific as, unlike ribavirin, it did not inhibit influenza A, influenza B or parainfluenza 2 virus. It was phosphorylated by adenosine kinase and, unlike ribavirin, it did not inhibit cellular inosine monophosphate dehydrogenase.


2018 ◽  
Vol 114 (3) ◽  
pp. 62a
Author(s):  
Matthew C. Johnson ◽  
Anika Burrell ◽  
Sajitha Anthony ◽  
Jeffrey Peterson ◽  
Justin Kollman

1997 ◽  
Vol 272 (7) ◽  
pp. 4458-4466 ◽  
Author(s):  
Jing Jin Gu ◽  
Jozef Spychala ◽  
Beverly S. Mitchell

2004 ◽  
Vol 48 (11) ◽  
pp. 4387-4394 ◽  
Author(s):  
Katyna Borroto-Esoda ◽  
Florence Myrick ◽  
Joy Feng ◽  
Jerry Jeffrey ◽  
Phillip Furman

ABSTRACT Amdoxovir [(−)-β-d-2,6-diaminopurine dioxolane (DAPD)] is a nucleoside analogue reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) replication. DAPD is deaminated by adenosine deaminase to the guanosine analogue dioxolane guanosine (DXG), which is subsequently phosphorylated to the corresponding 5′ triphosphate (DXG-TP). DXG-TP competes with the natural substrate dGTP for binding to the enzyme-nucleic acid complex. Mycophenolic acid (MPA) and ribavirin (RBV), inhibitors of inosine monophosphate dehydrogenase (IMPDH), inhibit the de novo synthesis of guanine nucleotides, including dGTP. Reducing the intracellular levels of dGTP would be expected to augment the antiviral activity of analogues of deoxyguanosine. In this study we examined the effect of MPA and RBV on the anti-HIV activity of DAPD and DXG. When tested against wild-type virus, both MPA and RBV decreased the 50% effective concentration (EC50) for DXG by at least 10-fold. In contrast, both MPA and RBV increase the EC50 value for zidovudine. MPA and RBV completely reversed the resistance to DXG observed with HIV isolates containing mutations which confer partial resistance to DAPD and DXG. Similarly, when tested against a mutant virus fully resistant to inhibition by DAPD (K65R/Q151M), MPA and RBV reduced the EC50 for DAPD to within twofold of that for the wild type. The combination of MPA or RBV with DAPD or DXG did not result in increased cytotoxicity or reduced levels of mitochondrial DNA when tested at physiologically relevant concentrations. These studies suggest a potential role for the use of IMPDH inhibitors in combination therapy with amdoxovir in the treatment of HIV.


2005 ◽  
Vol 281 (1) ◽  
pp. 206-212 ◽  
Author(s):  
YanShan Ji ◽  
JingJin Gu ◽  
Alexander M. Makhov ◽  
Jack D. Griffith ◽  
Beverly S. Mitchell

Sign in / Sign up

Export Citation Format

Share Document